Key predictive factors for efficacy of axitinib in first-line metastatic renal cell carcinoma: subgroup analysis in Japanese patients from a randomized, double-blind phase II study
Axitinib demonstrated clinical activity and safety in treatment-naïve Japanese patients with metastatic renal cell carcinoma. Multivariate analyses identified potential predictive factors for axitinib efficacy in first-line metastatic renal cell carcinoma.
Main Authors: | Tomita, Yoshihiko, Fukasawa, Satoshi, Oya, Mototsugu, Uemura, Hirotsugu, Shinohara, Nobuo, Habuchi, Tomonori, Rini, Brian I., Chen, Ying, Bair, Angel H., Ozono, Seiichiro, Naito, Seiji, Akaza, Hideyuki |
---|---|
Format: | Online |
Language: | English |
Published: |
Oxford University Press
2016
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5091032/ |
Similar Items
-
Efficacy and Safety of Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma: Subgroup Analysis of Japanese Patients from the Global Randomized Phase 3 AXIS Trial
by: Ueda, Takeshi, et al.
Published: (2013) -
Overall survival and final efficacy and safety results from a Japanese phase II study of axitinib in cytokine-refractory metastatic renal cell carcinoma
by: Eto, Masatoshi, et al.
Published: (2014) -
A multicenter phase I/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer
by: Akaza, Hideyuki, et al.
Published: (2016) -
A Phase 2 Trial of Abiraterone Acetate in Japanese Men with Metastatic Castration-resistant Prostate Cancer and without Prior Chemotherapy (JPN-201 Study)
by: Matsubara, Nobuaki, et al.
Published: (2014) -
Axitinib in Metastatic Renal Cell Carcinoma
by: Mittal, Kriti, et al.
Published: (2012)